AASLD Foundation Funds Over $1.5 Million in Hepatology Research and Career Development in 2022
Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest medical society...
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution
Ralf Weiskirchen – 14 August 2022
Clinical trials in hepatitis D virus: Measuring success
Ben L. Da – 14 August 2022 – Chronic hepatitis D infection results in the most severe form of chronic viral hepatitis but currently lacks effective treatment options. Therapy with pegylated interferon alpha is recommended for finite treatment duration by major liver societies. Still, it is plagued by low rates of sustained virologic response (SVR) and frequent relapses even if SVR is achieved. Recently, a wave of investigational therapies has come under evaluation, including bulevirtide, lonafarnib, pegylated interferon lambda, and REP‐2139 creating excitement with this viral infection.
Access to liver transplantation for patients with severe acute‐on‐chronic liver failure in Europe
Raveh Yehuda, Nicolau‐Raducu Ramona – 12 August 2022
Causes of variability in listing and access to liver transplantation for critically ill patients with cirrhosis: Acknowledging the elephant in the room
Thierry Artzner, Luca Belli, François Faitot, Rajiv Jalan – 12 August 2022
Novel approaches are needed to study social determinants of health in liver transplantation
Jin Ge, Jennifer C. Lai, Sharad I. Wadhwani – 12 August 2022
Low‐dose aspirin, rejection, and thrombosis: Is it the Wonder Drug® of liver transplantation?
Grace S. Lee‐Riddle, Juan P. Rocca – 11 August 2022
Letter to the editor: HCC EV ECG score: An extracellular vesicle–based protein assay for detection of early‐stage HCC
Wenhao Luo, Yu Gu, Taiping Zhang – 11 August 2022
Liver allocation policies for hepatocellular carcinoma have leveled the playing field—But who should be playing?
Allison J. Kwong, Neil Mehta – 11 August 2022